

Thoughtful Brands Inc.

09:00 19 Jun 2020

Mota Ventures taps Dr Markus Backmund as director of clinical research for psychedelic medicine subsidiary Verrian GmbH

Mota Ventures Corp (CSE:MOTA) (OTCMKTS:PEMTF) announced on Friday that it has appointed Professor Markus Backmund, as principal investigator and director of clinical research for its wholly-owned psychedelic medicine subsidiary, Verrian GmbH.

Dr Backmund serves as chair of the German Society of Addiction Medicine and is a pioneer in the field of addiction medicine.

Mota revealed on June 2 that it had completed its C\$20 million acquisition of European psychedelic medicine company Verrian, which specializes in products related to addiction reduction, with a laser focus on alcohol and opiates. The company operates a 110,000 square-foot pharmaceutical manufacturing facility in Radebuel, Germany.

READ: Mota Ventures appoints US actor and musician Roger C Clinton as member of Verrian's advisory board

Mota said Dr Backmund will play a "vital role" in spearheading the research efforts of its addiction medicine experts, resulting "in best of breed psychedelic derived treatments for the global marketplace."

In a statement, Mota Ventures CEO Ryan Hoggan said: "We're honoured to be working with a pioneer in addiction medicine, an authentic patient-first specialist like Dr Backmund, who has worked his entire career to change how patients who suffer from addiction are treated."

He added: "We are thrilled to be working with him in ground-breaking psychedelic and cannabis research as he continues to seek new treatments to help patients overcome addiction".

Dr Backmund is a medical doctor and specialist in infectious disease, internal medicine, emergency medicine, and addiction. He is also a professor at Ludwig Maximilians University in Munich, and the founder and co-editor of "Suchtmedizin" - the specialist Addiction Medicine Journal - and is the five-time chairman of the Board of the German Society for Addiction Medicine. He also runs the private clinic Praxiszentrum im Tal, an in-patient recovery center in Stanberg, Germany.

"The professional, human and sociopolitical challenges make addiction medicine the exciting field of medicine for me," said Dr Backmund.

In 1991, Dr Backmund's groundbreaking research project on "Qualified Withdrawal Treatment" evoked criticism. However, the results of his project are now the gold standard for alternative treatment methods in Germany. His approach to alternative addictions medicine focused on empirical results and on best outcomes for his patients,

Price: 0.07

Market Cap: \$14.71 m

1 Year Share Price Graph



December 2019 June 2020 November 20

Share Information

Code: TBI

Listing: CSE

52 week High Low
0.295 0.065

Sector: Cannabis

Website:

Company Synopsis:

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector.

action@proactiveinvestors.com

substantiating that patients need not suffer the mental and physical afflictions associated with withdrawal in order to conquer addiction.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Thoughtful Brands Inc. named herein, including the promotion by the Company of Thoughtful Brands Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).